1. Calvaruso V, et al. Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database. AASLD 2016 Poster 942
  2. Christensen S et al. Comorbidities, co-medication and potential drug to drug interactions in chronic hepatitis C patients (CHC): implications for adequate HCV treatment selection - data from a large transversal study in Germany and France. AASLD 2016. Poster 1971
  3. Koskinas J, et al. Efficacy and safety of direct acting antiviral(s) (DAA) containing regimens in the treatment of chronic hepatitis C (CHC) patients with genotype 3. A real life experience. AASLD 2016. Poster 2026
  4. Lionetti R et al. Daclatasvir in combination with other DAAs achieves high rate of virological clearance with excellent safety profile in liver tranplanted patients for hepatitis C. AASLD 2016. Poster 1633
  5. Madonia S, et al. Efficacy and safety of DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort. AASLD 2016 Poster 1930
  6. Mauss S, et al. Effectiveness of DACLATASVIR plus SOFOSBUVIR in HCV-GT3 patients – Results from the German Hepatitis C Registry (DHC-R). AASLD 2016 Poster 932
  7. Milan M, et al. Efficacy and safety of DAA-based oral therapy in a large cohort of HCV patients treated in clinical practice in Italy and monitored by the NAVIGATORE web-platform. AASLD 2016 Poster 960
  8. Pasulo L, et al. Genotype 3 infection in DAA era: preliminary reports of a real life Northern Italy Network For Viral Hepati-ti. AASLD 2016. Poster 1934
  9. Romano A, et al. Incidence and pattern of “de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs. AASLD 2016. Oral presentation 19
  10. Welzel TM, et al. Real-World Effectiveness and Safety of DAA Combination Therapies in Elderly Patients > 70 Years of Age in the German Hepatitis C-Registry (DHC-R). AASLD 2016 Poster 951
© Effetti srl